Alzamend Neuro ALZN
NASDAQ ALZN
$1.31 -0.04 (-2.96%)
At close: Nov 11, 2026 · 4:00 PM EST

Alzamend Neuro (ALZN) Total Debt (2024)

Updated

Alzamend Neuro (ALZN) reported Total Debt of $300,714 for fiscal Q4 2024 (quarter ended Apr 30, 2024).

Analysis

Alzamend Neuro (ALZN) Total Debt (2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 49.50 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 44.65 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 80.90 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 53.78 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -6.68 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 54.01 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 26.23 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 62.67 Bn
10 Alzamend Neuro 6.51 Mn -8.95 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Apr 30, 2024 300,714.00
API Access

Alzamend Neuro Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=ALZN&period=max&api_key=YOUR_API_KEY